Literature DB >> 8479999

Complications with facial advancement: a comparison between the Le Fort III and monobloc advancements.

J A Fearon1, L A Whitaker.   

Abstract

Certain procedures for facial advancement may carry greater risk than others. While many believe that separating the cranial base by monobloc advancement leads to a higher complication rate, no comparative series between the Le Fort III and monobloc advancements has ever been reported. We reviewed our series of these different techniques. Over a 15-year period, 29 patients underwent 30 surgical procedures, with either a midfacial or frontofacial advancement. The average age of patients at the time of surgery was 12 years, with a range from 3 to 26 years. There were 20 Le Fort III and 10 monobloc advancements. Follow-up averaged 4 years, with a range from 10 weeks to 13 years. There were no deaths in this series. The infectious complications differed significantly between the two groups, with all major infections occurring in the monobloc group. The noninfectious complications (2 major and 20 minor) were proportionately distributed between the Le Fort III and monobloc groups. Aesthetic results of the midface, judged by the percentage of revisions necessary, were found to be the same between the two procedures. Aesthetic results were noted to correlate strongly with age at the time of surgery, with the older patients being judged as having a better aesthetic result and most of the younger patients requiring a repeat of the facial advancement. We conclude that while we were unable to determine any definitive aesthetic advantage of one procedure over the other in our series, there was a significantly higher infection rate with the monobloc advancement. On the basis of these results, we recommend a staging of the forehead and midfacial advancements.

Entities:  

Mesh:

Year:  1993        PMID: 8479999

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  9 in total

1.  Midface Morphology and Growth in Syndromic Craniosynostosis Patients Following Frontofacial Monobloc Distraction.

Authors:  Cristiano Tonello; Lucia H S Cevidanes; Antonio C O Ruellas; Nivaldo Alonso
Journal:  J Craniofac Surg       Date:  2021 Jan-Feb 01       Impact factor: 1.046

Review 2.  Complications of frontofacial advancement.

Authors:  David J Dunaway; Johnathan A Britto; Christopher Abela; Robert D Evans; N U Owase Jeelani
Journal:  Childs Nerv Syst       Date:  2012-08-08       Impact factor: 1.475

3.  An Update on Midface Advancement Using Le Fort II and III Distraction Osteogenesis.

Authors:  Youssef Tahiri; Jesse Taylor
Journal:  Semin Plast Surg       Date:  2014-11       Impact factor: 2.314

4.  Advances in the Treatment of Syndromic Midface Hypoplasia Using Monobloc and Facial Bipartition Distraction Osteogenesis.

Authors:  Anand R Kumar; Derek Steinbacher
Journal:  Semin Plast Surg       Date:  2014-11       Impact factor: 2.314

Review 5.  Revisiting Crouzon syndrome: reviewing the background and management of a multifaceted disease.

Authors:  Samuel N Helman; Arvind Badhey; Sameep Kadakia; Eugene Myers
Journal:  Oral Maxillofac Surg       Date:  2014-09-24

6.  Maxillary distraction osteogenesis at Le Fort-I level induces bone apposition at infraorbital rim.

Authors:  Vidya Rattan; Ashok Kumar Jena; Satinder Pal Singh; Ashok Kumar Utreja
Journal:  Clin Oral Investig       Date:  2013-11-26       Impact factor: 3.573

7.  Pediatric craniofacial surgery for craniosynostosis: Our experience and current concepts: Parts -2.

Authors:  Y N Anantheswar; N K Venkataramana
Journal:  J Pediatr Neurosci       Date:  2009-07

8.  An Unoperated Crouzon Family Treated with Monobloc Distraction: Challenges and Lessons.

Authors:  Justin Hart; Stephen Lu; Konstantinos Gasteratos; Kongkrit Chaiyasate
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-11-02

9.  Monoblock craniofacial internal distraction in a child with Pfeiffer syndrome: a case report.

Authors:  Jaiho Chung; Dong Ha Park; Soo Han Yoon
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.